Investor s Fiduciary Advisor Network LLC Makes New $2.48 Million Investment in Eli Lilly and Company (NYSE:LLY)

Investor s Fiduciary Advisor Network LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,216 shares of the company’s stock, valued at approximately $2,482,000. Eli Lilly and Company accounts for approximately 1.0% of Investor s Fiduciary Advisor Network LLC’s investment portfolio, making the stock its 25th largest holding.

Several other institutional investors also recently bought and sold shares of LLY. FPC Investment Advisory Inc. increased its position in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company in the 4th quarter worth approximately $50,000. Fiduciary Advisors Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $58,000. Finally, Bellwether Advisors LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $66,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. UBS Group dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,002.80.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $736.21 on Friday. The business’s 50 day moving average price is $810.98 and its 200 day moving average price is $810.88. The company has a market cap of $697.73 billion, a price-to-earnings ratio of 62.87, a PEG ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the firm posted $2.58 EPS. The company’s revenue was up 45.2% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.